At age 16, Sangeeta Bhatia’s parents outlined three future career choices for her:  doctor, engineer, or entrepreneur.  Questioning the basic assumption of choice, Sangeeta simply became all three – and each at world-class level.  As the Director of MIT’s Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research, she produces world-class research and entrepreneurial ventures on the intersections of biotech, medicine, nanotechnology, engineering, and computer science.  This broad scope made her one of the youngest persons in history to be elected to all three National Academies for Sciences, Medicine, and Engineering.  Then, Sangeeta continued with the National Academy of Inventors and the American Academy of Arts and Sciences, for the complete set.

Now, she is working on the miniaturization of medical devices combined with synthetic biology.  She has founded 8 companies, among them Glympse Bio, an innovative synthetic cancer sensor technology (merged with Sunbird), Satellite Bio, a cell therapy company, and Impilo Therapeutics, focused on targeted RNA delivery.

Before all that, however, Sangeeta’s first love story was… the liver.  Her PhD work was about keeping liver cells functioning outside of the body, so one of her team’s inventions is a human “microliver” that models liver disease and allows testing responsive engineered nanoparticles to diagnose, study, and treat diseases.

Today, Sangeeta’s love stories go beyond the liver, and also include her husband Jagesh, and her two daughters.

‍